INVENTIVA ADS/1 O.N. (6IVA) - Net Assets
Based on the latest financial reports, INVENTIVA ADS/1 O.N. (6IVA) has net assets worth €-28.52 Million EUR (≈ $-33.35 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€249.51 Million ≈ $291.70 Million USD) and total liabilities (€278.03 Million ≈ $325.05 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check INVENTIVA ADS/1 O.N. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-28.52 Million |
| % of Total Assets | -11.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 60.8 |
INVENTIVA ADS/1 O.N. - Net Assets Trend (2021–2025)
This chart illustrates how INVENTIVA ADS/1 O.N.'s net assets have evolved over time, based on quarterly financial data. Also explore INVENTIVA ADS/1 O.N. asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for INVENTIVA ADS/1 O.N. (2021–2025)
The table below shows the annual net assets of INVENTIVA ADS/1 O.N. from 2021 to 2025. For live valuation and market cap data, see INVENTIVA ADS/1 O.N. market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-28.52 Million ≈ $-33.35 Million |
+73.26% |
| 2024-12-31 | €-106.65 Million ≈ $-124.68 Million |
-232.95% |
| 2023-12-31 | €-32.03 Million ≈ $-37.45 Million |
-170.43% |
| 2022-12-31 | €45.48 Million ≈ $53.17 Million |
-48.83% |
| 2021-12-31 | €88.87 Million ≈ $103.89 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to INVENTIVA ADS/1 O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30450300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €325.62 Million | % |
| Total Equity | €-28.52 Million | 100.00% |
INVENTIVA ADS/1 O.N. Competitors by Market Cap
The table below lists competitors of INVENTIVA ADS/1 O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sweetgreen Inc
NYSE:SG
|
$957.64 Million |
|
Shanghai Haohai Biological Tech Co
SHG:688366
|
$957.73 Million |
|
LuxExperience B.V.
NYSE:LUXE
|
$958.09 Million |
|
Berliner Effektengesellschaft AG
F:BFV
|
$958.18 Million |
|
Rezolve AI Limited Ordinary Shares
NASDAQ:RZLV
|
$957.19 Million |
|
Jupiter Life Line Hospitals Limited
NSE:JLHL
|
$957.18 Million |
|
Lampsa Hellenic Hotels S.A
AT:LAMPS
|
$957.11 Million |
|
Cangzhou Dahua Co Ltd
SHG:600230
|
$957.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INVENTIVA ADS/1 O.N.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -106,646,000 to -28,522,000, a change of 78,124,000.
- Net loss of 354,138,000 reduced equity.
- New share issuances of 206,441,000 increased equity.
- Other factors increased equity by 225,821,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-354.14 Million | -1241.63% |
| Share Issuances | €206.44 Million | +723.8% |
| Other Changes | €225.82 Million | +791.74% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares INVENTIVA ADS/1 O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.17 | €4.38 | x |
| 2022-12-31 | €1.08 | €4.38 | x |
| 2023-12-31 | €-0.61 | €4.38 | x |
| 2024-12-31 | €-1.11 | €4.38 | x |
| 2025-12-31 | €-0.15 | €4.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INVENTIVA ADS/1 O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7899.58%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-35.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -55.85% | -1183.48% | 0.03x | 1.37x | €-58.52 Million |
| 2022 | -119.35% | -445.64% | 0.10x | 2.55x | €-58.82 Million |
| 2023 | 0.00% | -631.84% | 0.25x | 0.00x | €-107.22 Million |
| 2024 | 0.00% | -2002.74% | 0.08x | 0.00x | €-173.55 Million |
| 2025 | 0.00% | -7899.58% | 0.02x | 0.00x | €-351.29 Million |
Industry Comparison
This section compares INVENTIVA ADS/1 O.N.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,132,095,555
- Average return on equity (ROE) among peers: -68.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INVENTIVA ADS/1 O.N. (6IVA) | €-28.52 Million | -55.85% | N/A | $957.19 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $242.58 Million | -85.63% | 0.52x | $204.16 Million |
| PreveCeutical Medical Inc (18H) | $-2.29 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.05 Billion | -15.51% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $1.82 Billion |
| BioNTech SE (22UA) | $19.22 Billion | -5.91% | 0.14x | $20.05 Billion |
About INVENTIVA ADS/1 O.N.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more